Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAUL: Atezolizumab in advanced urinary tract carcinoma
NCT02928406Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2016
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 32
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in transitional cell carcinoma (TCC), sponsored by Roche. Primary endpoint: Percentage of Participants With Adverse Events up to 6 years. Started Nov 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT02928406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928406.